Teladoc Mergers and Acquisitions Presentation Deck

Together, Teladoc Health and Livongo Deliver Substantial Value for Shareholders 40% -45% Pre-Synergy YoY Revenue Growth in 2021 30% - 40% Pre-Synergy '20'23 Revenue CAGR 15% - 18% Pre-Synergy Adj. EBITDA Margin by 2023 200-300bps Annual Expansion Teladoc Livongo® HEALTH $100M Run-rate Revenue Synergies by 2022 $500M Run-rate Revenue Synergies by 2025 $60M Run-rate Cost Savings by 2022 O Teladoc Health, Inc. All rights reserved. 13

View entire presentation